AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB. The purchase price is divided into a smaller amount as initial payment at the time of takeover and an additional payment based on Glactone Pharma’s future performance.
http://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.png00Aqilionhttp://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.pngAqilion2019-12-09 08:00:082019-12-09 08:00:08Aqilion sells shareholdings in portfolio company Glactone Pharma
Aqilion is strengthening its portfolio with the addition of two innovative preclinical projects, Alhena and Alnitak. The company is overseeing the two pharmaceutical projects, which both fall under Aqilion’s new focus area: inflammation at the interface of oncology and immunology.
http://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.png00Aqilionhttp://aqilion.com/wp-content/uploads/2019/03/aqilion_logo_main.pngAqilion2019-12-04 08:00:002019-12-04 08:00:00Aqilion strengthens its portfolio with two innovative pharmaceutical projects in the fields of inflammation and oncology
Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on November 1, 2019. Adenovir Pharma developed an antiviral medication (APD-209) to treat and potentially even to prevent the contagious eye disease epidemic keratoconjunctivitis (EKC), which is […]
Aqilion identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market.
The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner.
Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
Other external services
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds: